Glucocorticoid-induced osteoporosis

Summary

Glucocorticoid-induced osteoporosis (MONDO:0000757) is a disease and 5 clinical trials. Top therapeutic interventions include alendronic acid, denosumab, and romosozumab. A subtype of corticosteroid-induced osteoporosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	glucocorticoid-induced osteoporosis
Mondo ID	MONDO:0000757
DOID	DOID:0060343
Is cancer (heuristic)	no

Disease family

This is a subtype of corticosteroid-induced osteoporosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone remodeling disease › bone resorption disease › osteoporosis › drug-induced osteoporosis › corticosteroid-induced osteoporosis › glucocorticoid-induced osteoporosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	2
PHASE3	1
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06588153	PHASE4	ACTIVE_NOT_RECRUITING	A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT04091243	PHASE4	COMPLETED	Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users
NCT03164928	PHASE3	COMPLETED	Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
NCT02418273	PHASE1/PHASE2	WITHDRAWN	Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
NCT05397938	PHASE2	UNKNOWN	Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALENDRONIC ACID	4	2
DENOSUMAB	4	2
ROMOSOZUMAB	4	1